The Inhaled Drug Delivery Conference series is one of the most respected and mature meetings in this field. It has recently metamorphosed into a more current hot topic approach and extended its reach by including a new poster session and a pre-conference workshop. The poster session is very exciting as it permits companies and academic institutions to show off their research and field of expertise in inhaled drug delivery. The best scientific poster receives a prize of 500 euros and an opportunity to return to the next conference to make a podium presentation on their work. Entries to the scientific poster competition must register to attend the event and a discounted rate is available for academics. The aim of the workshop is to particularly focus on issues we practically face today and in the immediate future, it will include real examples and experiences of others within the industry so that best practices can be shared.

Because the IDD conference is well respected and provides content that is current, the attendees are some of the key movers and shakers from the industry from fields of technology, product development, business development and regulatory affairs, thereby, making it an ideal place for successful networking. Indeed the organisers will help facilitate one-to-one meetings should you have a particular requirement to meet with a participant or speaker.

Inhaled Drug Delivery continues to be a very significant delivery approach that has undergone further advances in the recent years. A number of topics are pivotal at this time and in the near future, as Inhaled Drug Delivery embraces the growth of generic product opportunities and continues to extend to delivering a broad spectrum of systemic drugs.

The Inhaled Drug Delivery conference will focus on some current hot topics and provide updates on some of the most exciting innovations in this field. A key session is understanding Bioequivalence (BE), what the guidance states and how to interpret this. Once this has been achieved putting it into practice is another hurdle. The programme includes several presentations on BE issues and practical examples of approaching BE for inhaled products.
The next topic focuses on device technology and some new and innovative advances are discussed, including the application of GPS and wireless technology to inhalers. These technologies have been discussed for a number of years, but now it seems that practical solutions have been found that provide exciting new potential applications in this field to aid both patients and prescribers.

We focus on Systemic delivery, here some very exciting developments have occurred which are nearing late stage trials or approval application. Perhaps the one everyone has been following is that of inhaled Insulin. We know that the big Pharma players have pulled out of their development programs leaving the smaller MannKind Corporation leading this activity. We shall have an exclusive update from MannKind on their product and its status; this will be very interesting as an NDA has recently been submitted. Apart from inhaled Insulin we have updates on inhaled Fentanyl, Loxapine and Ciprofloxacin. Each of these molecules is for a different therapeutic indication and each presents significantly different challenges in developing them into inhaled products and to receive regulatory approval.

This meeting will also consider how modern engineered particles can be used in inhaled drug delivery, how a new aqueous delivery technology could utilise a ‘mature’ drug for children potentially replacing steroid use, and finally will examine the recent chemical link that has been identified between Eczema and Asthma. A link that has been proposed for many years and has now been demonstrated in animal studies, thus opening up our mechanistic understanding further and providing a potential new range of Asthma drugs.

In all, this conference promises to be very current and of significant practical use to the inhaled product development industry.

For more information and to register: [http://www.management-forum.co.uk/medical/eventid/1086](http://www.management-forum.co.uk/medical/eventid/1086)